Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Salt'n'Peppa who wrote (7075)	4/3/2001 3:00:59 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

S&P, The quarterly numbers should at least have the Provalis up front and may (there is debate on this) have the revenue for the February shipment. If both are there a profit is possible. Doesn't matter really. Joe, How many have Refco picked up today? Wolf

To: Salt'n'Peppa who wrote (7075)	4/3/2001 3:03:59 PM
From: SofaSpud	Respond to of 14101

OT Interesting -- I just got a fairly breathless report in my email on ONC: From Lightyear Capital: We recently discussed a number of promising new developments in the research and clinical trial programs with Oncolytics Biotech (ONC:TSE), a Calgary-based biotechnology company developing the human reovirus as an anti-cancer therapy. We are pleased with the company’s progress to date and we are reiterating our STRONG BUY recommendation. Please see page 3 for the complete company note. Dr. Joseph Tucker – Biotechnology Analyst ONC down a buck, or 12%. Go fig.